Quarterly ResultAug 5, 2026, 04:20 PM
Standard BioTools Q2 Revenue $20.1M; Adjusted EBITDA -$2.5M; Treeline Merger On Track
AI Summary
Standard BioTools Inc. announced its second quarter 2026 financial results, reporting revenue of $20.1 million, a 7.6% decrease year-over-year. Despite the revenue decline, the company achieved an 84% improvement in adjusted EBITDA, narrowing its loss to $2.5 million, and a 1% improvement in operating loss to $25.4 million. The company also confirmed that its merger with Treeline Biosciences is progressing and is expected to close before year-end 2026, leading to the withdrawal of its full-year 2026 revenue outlook.
Key Highlights
- Q2 2026 revenue was $20.1 million, a 7.6% decrease year-over-year.
- Adjusted EBITDA for Q2 2026 was a loss of $2.5 million, an 84% improvement year-over-year.
- Operating loss for Q2 2026 was $25.4 million, a 1% improvement year-over-year.
- Merger with Treeline Biosciences is progressing and anticipated to close before year-end 2026.
- Full year 2026 revenue outlook has been withdrawn due to the pending merger.
- Cash, cash equivalents, and investments totaled $541.1 million as of June 30, 2026.
- Non-GAAP gross margin improved to 56.3% in Q2 2026 from 54.1% in Q2 2025.
- Non-GAAP operating expenses decreased 50% year-over-year to $13.8 million in Q2 2026.
Price Impact
More from LAB